Raphael Pharmaceutical Inc. is a pharmaceutical drug research and development company. The Company is focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol (CBD) oil. The Company has completed the study for its lead product candidate for the treatment of rheumatoid arthritis (RA), and is developing asthma product candidates, which are in the pre-clinical-stage. The Company is also continuing to investigate its product for the treatment of autoimmune diseases. The Companyâ€™s discovery platform focuses on the use of CBD oil, one of the cannabinoids in cannabis plants, as the active pharmaceutical ingredient (API), for its RA product candidate and COVID-19 product candidate.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Delayed OTC Markets Other stock markets 09:34:17 2026-04-29 EDT			5-day change	1st Jan Change
1.400 ^USD	+2,592.31%		-.--%	-

05-14	Raphael Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-31	Raphael Pharmaceutical Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	28.25M 24.72M 22.82M 21.29M 40.11M 2.67B 40.83M 274M 106M 1.32B 106M 104M 4.59B	P/E 2024	-3.2x	P/E 2025	-21.4x
Enterprise Value	28.24M 24.71M 22.81M 21.28M 40.1M 2.67B 40.82M 274M 106M 1.32B 106M 104M 4.59B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	53.88%	Yield 2024 *	-	Yield 2025	-

05-14	Raphael Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-31	Raphael Pharmaceutical Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	Raphael Pharmaceutical Inc. Auditor Raises 'Going Concern' Doubt	CI
03-24	Raphael Pharmaceutical Inc. Announces Cessation of Yehuda Eliya from Board of Directors, Effective December 31, 2025	CI
11-17	Raphael Pharmaceutical Inc. Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid Arthritis	CI
11-13	Raphael Pharmaceutical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-13	Raphael Pharmaceutical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-11	Raphael Pharmaceutical Inc. Announces Directorate Changes	CI
25-08-11	Raphael Pharmaceutical Inc. Completes Its Product Development and Is Ready to Launch Its Proprietary Natural Formula Under the Raphawell Brand for Rheumatoid Arthritis Support in the United States	CI
25-05-15	Raphael Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-03-31	Raphael Pharmaceutical Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-03-30	Raphael Pharmaceutical Inc. Auditor Raises 'Going Concern' Doubt	CI
25-01-14	Raphael Pharmaceutical Inc. Announces Board Changes	CI

11-17	Raphael Pharmaceutical Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid Arthritis (RA)	AQ
25-01-07	Raphael Pharmaceutical Announces Positive Proof-of-Concept Clinical Study Results for the Company’s Cannabinoid-Based Formula for the Treatment of Rheumatoid Arthritis	AQ
24-07-09	Raphael Pharmaceutical Issues Letter to Shareholders	AQ
24-06-26	Raphael Pharmaceutical : Certificate of Incorporation/Bylaws Form 8 K	PU
23-03-28	RAPHAEL PHARMACEUTICAL INC. : Other Events (form 8-K)	AQ

Raphael Pharmaceutical Inc. Stock

Stocks

RAPH

US27785B2088

Biotechnology & Medical Research

Valuation: Raphael Pharmaceutical Inc.

Chart: Raphael Pharmaceutical Inc.

Latest news : Raphael Pharmaceutical Inc.

Press Releases: Raphael Pharmaceutical Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Raphael Pharmaceutical Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

Current year	0.05	1.4
1 year	0.04	1.4
3 years	0.04	1.67
5 years	0.04	2.5
10 years	0.04	2.5

Manager	Title	Age	Since
Shlomo Pilo CEO	Chief Executive Officer	73	2021-05-13
Guy Ofir DFI	Director of Finance/CFO	54	2021-09-26
Igal Louria-Hayon CTO	Chief Tech/Sci/R&D Officer	53	2021-09-26

Director	Title	Age	Since
Guy Ofir BRD	Director/Board Member	54	2021-09-26
Shlomo Pilo CHM	Chairman	73	2022-06-29
Ajay Kumar Dhadha CHM	Chairman	80	2025-01-07

Date	Insider	Type	Main position	Quantity	% Market Cap.
11-19	Igal Louria-Hayon	Option	Chief Technology Officer	700,000	3.5666%
25-03-04	Ajay Kumar Dhadha	Free	Chairman	600,000	3.2083%
25-03-01	Shlomo Pilo	Free	Chief Executive Officer	300,000	1.6042%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RAPHAEL PHARMACEUTICAL INC.	+2,592.31%	-.--%	+86.67%	-3.45%	28.25M
LONZA GROUP AG	+1.15%	+5.94%	-3.40%	+2.32%	46.62B
REVOLUTION MEDICINES, INC.	-4.03%	+9.49%	+404.48%	+593.83%	40.95B
IQVIA HOLDINGS INC.	+0.06%	+12.93%	+22.74%	-13.95%	32.26B
BEONE MEDICINES AG	-1.55%	+3.07%	+17.58%	+59.63%	32.24B
CELLTRION, INC.	-3.29%	+2.85%	+13.80%	+30.30%	25.53B
ASCENDIS PHARMA A/S	+1.40%	+12.00%	-	-	16.38B
MEDPACE HOLDINGS, INC.	-0.61%	+12.87%	+70.27%	+122.52%	15.27B
EUROFINS SCIENTIFIC SE	+0.56%	+5.09%	+13.43%	+17.88%	13.61B
IONIS PHARMACEUTICALS, INC.	-1.60%	+4.50%	+100.99%	+93.54%	13.34B
Average	+258.48%	+9.29%	+80.73%	+100.29%	23.62B
Weighted average by Cap.	-0.65%	+10.36%	+93.99%	+136.61%

	2024	2025
Net sales	-	-
Net income	-1.52M -1.33M -1.23M -1.14M -2.16M -144M -2.2M -14.72M -5.72M -70.87M -5.71M -5.58M -247M	-1.28M -1.12M -1.03M -964K -1.82M -121M -1.85M -12.4M -4.81M -59.68M -4.81M -4.7M -208M
Net Debt	22K 19.26K 17.78K 16.58K 31.24K 2.08M 31.8K 213K 82.78K 1.03M 82.65K 80.81K 3.58M	-11K -9.63K -8.89K -8.29K -15.62K -1.04M -15.9K -107K -41.39K -513K -41.33K -40.4K -1.79M